vs
Side-by-side financial comparison of HAEMONETICS CORP (HAE) and Revolve Group, Inc. (RVLV). Click either name above to swap in a different company.
HAEMONETICS CORP is the larger business by last-quarter revenue ($339.0M vs $324.4M, roughly 1.0× Revolve Group, Inc.). HAEMONETICS CORP runs the higher net margin — 13.2% vs 5.7%, a 7.5% gap on every dollar of revenue. On growth, Revolve Group, Inc. posted the faster year-over-year revenue change (10.4% vs -2.7%). HAEMONETICS CORP produced more free cash flow last quarter ($87.2M vs $-13.3M). Over the past eight quarters, Revolve Group, Inc.'s revenue compounded faster (9.5% CAGR vs 0.4%).
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
Revolve Theatre Company is a Henley-on-Thames based theatre company specialising in political and Shakespearean plays. The company is owned by Oliver Dench, Joe Morris and Tom Smith.
HAE vs RVLV — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $339.0M | $324.4M |
| Net Profit | $44.7M | $18.6M |
| Gross Margin | 59.7% | 53.3% |
| Operating Margin | 19.9% | 6.3% |
| Net Margin | 13.2% | 5.7% |
| Revenue YoY | -2.7% | 10.4% |
| Net Profit YoY | 19.3% | 50.4% |
| EPS (diluted) | $0.95 | $0.27 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $339.0M | $324.4M | ||
| Q3 25 | $327.3M | $295.6M | ||
| Q2 25 | $321.4M | $309.0M | ||
| Q1 25 | $330.6M | $296.7M | ||
| Q4 24 | $348.5M | $293.7M | ||
| Q3 24 | $345.5M | $283.1M | ||
| Q2 24 | $336.2M | $282.5M | ||
| Q1 24 | — | $270.6M |
| Q4 25 | $44.7M | $18.6M | ||
| Q3 25 | $38.7M | $21.2M | ||
| Q2 25 | $34.0M | $10.2M | ||
| Q1 25 | $58.0M | $11.8M | ||
| Q4 24 | $37.5M | $12.3M | ||
| Q3 24 | $33.8M | $11.0M | ||
| Q2 24 | $38.4M | $15.4M | ||
| Q1 24 | — | $10.9M |
| Q4 25 | 59.7% | 53.3% | ||
| Q3 25 | 59.5% | 54.6% | ||
| Q2 25 | 59.8% | 54.1% | ||
| Q1 25 | 58.4% | 52.0% | ||
| Q4 24 | 55.5% | 52.5% | ||
| Q3 24 | 54.2% | 51.2% | ||
| Q2 24 | 52.0% | 54.0% | ||
| Q1 24 | — | 52.3% |
| Q4 25 | 19.9% | 6.3% | ||
| Q3 25 | 17.9% | 7.1% | ||
| Q2 25 | 16.8% | 5.8% | ||
| Q1 25 | 21.6% | 5.0% | ||
| Q4 24 | 16.9% | 3.9% | ||
| Q3 24 | 15.0% | 5.0% | ||
| Q2 24 | 11.8% | 5.8% | ||
| Q1 24 | — | 3.4% |
| Q4 25 | 13.2% | 5.7% | ||
| Q3 25 | 11.8% | 7.2% | ||
| Q2 25 | 10.6% | 3.3% | ||
| Q1 25 | 17.5% | 4.0% | ||
| Q4 24 | 10.8% | 4.2% | ||
| Q3 24 | 9.8% | 3.9% | ||
| Q2 24 | 11.4% | 5.4% | ||
| Q1 24 | — | 4.0% |
| Q4 25 | $0.95 | $0.27 | ||
| Q3 25 | $0.81 | $0.29 | ||
| Q2 25 | $0.70 | $0.14 | ||
| Q1 25 | $1.17 | $0.16 | ||
| Q4 24 | $0.74 | $0.18 | ||
| Q3 24 | $0.66 | $0.15 | ||
| Q2 24 | $0.74 | $0.21 | ||
| Q1 24 | — | $0.15 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $363.4M | $292.3M |
| Total DebtLower is stronger | $1.2B | — |
| Stockholders' EquityBook value | $911.5M | $512.5M |
| Total Assets | $2.5B | $765.0M |
| Debt / EquityLower = less leverage | 1.34× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $363.4M | $292.3M | ||
| Q3 25 | $296.4M | $315.4M | ||
| Q2 25 | $292.9M | $310.7M | ||
| Q1 25 | $306.8M | $300.8M | ||
| Q4 24 | $320.8M | $256.6M | ||
| Q3 24 | $299.3M | $252.8M | ||
| Q2 24 | $344.4M | $244.7M | ||
| Q1 24 | — | $273.4M |
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $911.5M | $512.5M | ||
| Q3 25 | $849.2M | $490.2M | ||
| Q2 25 | $882.3M | $468.6M | ||
| Q1 25 | $820.8M | $453.4M | ||
| Q4 24 | $906.9M | $437.8M | ||
| Q3 24 | $878.9M | $420.8M | ||
| Q2 24 | $905.4M | $405.8M | ||
| Q1 24 | — | $389.9M |
| Q4 25 | $2.5B | $765.0M | ||
| Q3 25 | $2.4B | $751.3M | ||
| Q2 25 | $2.5B | $722.9M | ||
| Q1 25 | $2.5B | $713.9M | ||
| Q4 24 | $2.5B | $665.5M | ||
| Q3 24 | $2.5B | $670.9M | ||
| Q2 24 | $2.5B | $657.8M | ||
| Q1 24 | — | $650.0M |
| Q4 25 | 1.34× | — | ||
| Q3 25 | 1.44× | — | ||
| Q2 25 | 1.39× | — | ||
| Q1 25 | 1.49× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $93.6M | $-10.2M |
| Free Cash FlowOCF − Capex | $87.2M | $-13.3M |
| FCF MarginFCF / Revenue | 25.7% | -4.1% |
| Capex IntensityCapex / Revenue | 1.9% | 1.0% |
| Cash ConversionOCF / Net Profit | 2.09× | -0.55× |
| TTM Free Cash FlowTrailing 4 quarters | $308.1M | $48.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $93.6M | $-10.2M | ||
| Q3 25 | $111.3M | $11.8M | ||
| Q2 25 | $17.4M | $12.6M | ||
| Q1 25 | $116.6M | $45.1M | ||
| Q4 24 | $43.8M | $3.9M | ||
| Q3 24 | $48.8M | $9.1M | ||
| Q2 24 | $-27.4M | $-24.7M | ||
| Q1 24 | — | $38.4M |
| Q4 25 | $87.2M | $-13.3M | ||
| Q3 25 | $106.3M | $7.5M | ||
| Q2 25 | $13.6M | $10.4M | ||
| Q1 25 | $100.9M | $43.4M | ||
| Q4 24 | $35.2M | $2.1M | ||
| Q3 24 | $39.4M | $8.0M | ||
| Q2 24 | $-33.1M | $-25.7M | ||
| Q1 24 | — | $36.7M |
| Q4 25 | 25.7% | -4.1% | ||
| Q3 25 | 32.5% | 2.5% | ||
| Q2 25 | 4.2% | 3.4% | ||
| Q1 25 | 30.5% | 14.6% | ||
| Q4 24 | 10.1% | 0.7% | ||
| Q3 24 | 11.4% | 2.8% | ||
| Q2 24 | -9.8% | -9.1% | ||
| Q1 24 | — | 13.5% |
| Q4 25 | 1.9% | 1.0% | ||
| Q3 25 | 1.5% | 1.5% | ||
| Q2 25 | 1.2% | 0.7% | ||
| Q1 25 | 4.7% | 0.6% | ||
| Q4 24 | 2.5% | 0.6% | ||
| Q3 24 | 2.7% | 0.4% | ||
| Q2 24 | 1.7% | 0.4% | ||
| Q1 24 | — | 0.6% |
| Q4 25 | 2.09× | -0.55× | ||
| Q3 25 | 2.88× | 0.56× | ||
| Q2 25 | 0.51× | 1.24× | ||
| Q1 25 | 2.01× | 3.82× | ||
| Q4 24 | 1.17× | 0.32× | ||
| Q3 24 | 1.44× | 0.83× | ||
| Q2 24 | -0.71× | -1.60× | ||
| Q1 24 | — | 3.53× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
RVLV
| Fashion Apparel | $155.1M | 48% |
| Dresses | $76.4M | 24% |
| Handbags Shoes And Accessories | $67.6M | 21% |
| Beauty | $20.3M | 6% |
| Manufactured Product Other | $5.0M | 2% |
| Breakage On Store Credit And Gift Cards | $900.0K | 0% |
